2024
Published research on the human health implications of climate change between 2012 and 2021: cross sectional study
Bartlett V, Doernberg H, Mooghali M, Gupta R, Wallach J, Nyhan K, Chen K, Ross J. Published research on the human health implications of climate change between 2012 and 2021: cross sectional study. BMJ Medicine 2024, 3: e000627. PMID: 38352020, PMCID: PMC10862342, DOI: 10.1136/bmjmed-2023-000627.Peer-Reviewed Original ResearchHealth effects of climate changeHealth research fundingRandom sampleHealth effectsCross sectional studyPeer-reviewed researchWeb of ScienceGrey literatureHealth conditionsSectional studyInclusion criteriaRisk populationHealthHealth impactsHealth implicationsGoogle ScholarResearch articlesNational InstituteFunding sourcesPublication characteristicsResearch fundingPublished researchRiskDisproportionate focusPopulation
2021
Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of Experts
Hurley N, Berkowitz A, Masoudi F, Ross J, Desai N, Shah N, Dhruva S, Mortazavi B. Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of Experts. 2021, 00: 1-4. DOI: 10.1109/bhi50953.2021.9508568.Peer-Reviewed Original Research
2018
Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population
Warner F, Dhruva SS, Ross JS, Dey P, Murugiah K, Krumholz HM. Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open 2018, 8: e021685. PMID: 30037874, PMCID: PMC6059296, DOI: 10.1136/bmjopen-2018-021685.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialFramingham risk scoreCardiovascular riskRisk scoreStudy populationStudy participantsNon-diabetic adultsTotal study populationHigh-risk populationClinical trial dataClinical trial sitesTrial populationIntervention trialsRisk populationsNew England JournalIndependent investigatorsTrial dataSecondary analysisSPRINT trialSPRINT dataTrialsRiskScoresParticipantsPopulationFactors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis
Zeitoun J, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis. Clinical Pharmacology & Therapeutics 2018, 104: 1000-1007. PMID: 29377075, DOI: 10.1002/cpt.1038.Peer-Reviewed Original Research
2014
Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada
Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. American Heart Journal 2014, 167: 683-689. PMID: 24766978, PMCID: PMC4215424, DOI: 10.1016/j.ahj.2014.01.014.Peer-Reviewed Original ResearchConceptsUse of ezetimibeENHANCE trialEzetimibe useProgression of atherosclerosisMain outcome measuresAtherosclerosis regression trialsMonthly numberOutcome measuresRegression trialsEzetimibeIMS HealthCommon evidence baseEvidence baseTrialsUnited StatesUtilization patternsFurther investigationDifferent utilization patternsPopulationDifferent patternsUse trendsAtherosclerosisSimvastatinProgression
2011
US Cardiologist Workforce From 1995 To 2007: Modest Growth, Lasting Geographic Maldistribution Especially In Rural Areas
Aneja S, Ross JS, Wang Y, Matsumoto M, Rodgers GP, Bernheim SM, Rathore SS, Krumholz HM. US Cardiologist Workforce From 1995 To 2007: Modest Growth, Lasting Geographic Maldistribution Especially In Rural Areas. Health Affairs 2011, 30: 2301-2309. PMID: 22147857, PMCID: PMC3332098, DOI: 10.1377/hlthaff.2011.0255.Peer-Reviewed Original ResearchConceptsPrimary care physiciansCare physiciansGeographic maldistributionChronic cardiovascular diseaseHospital referral regionsUse of telemedicineCardiology workforceNumber of cardiologistsTotal physician workforceCardiovascular diseaseCardiovascular careReferral regionsElderly populationUS populationTotal physiciansCardiologistsPhysiciansAge sixtyPhysician workforceDisadvantaged areasPercentRural areasPopulationDiseaseVariety of strategiesUse of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials